HIV

Latest News


Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

CME Content


The National Cancer Institute (NCI) is sponsoring an ongoing clinical trial that evaluates pembrolizumab in people with HIV who have relapsed or refractory cancer and are also taking antiretroviral therapy. People with HIV are often excluded from participating in clinical trials of new cancer treatments because of concerns that treatments may be unsafe for them.

A multidisciplinary panel of HIV experts gathered in October 2016 to discuss the current state of HIV care and develop critical recommendations for Pharmacy and Therapeutics (P&T) committee members to consider when developing policies affecting their member populations who are living with HIV. This paper presents the panel’s discussion, consensus opinion, and conclusions.

Underinsurance, which occurs when people have insurance but aren't covered for services they need, is a serious problem in the US, according to A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan. He proposed some strategies to alleviate this phenomenon, like smarter deductibles and revised Internal Revenue Service (IRS) rules.

The annual health information technology issue (IT) of The American Journal of Managed Care looks at the purpose for the decade-long move away from paper to technology-based infrastructure: better delivery of care to populations. As special guest editor Dr. Joshua R. Vest and other authors note, there is progress, but we’re not there yet.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo